Double-stranded DNA at 5′-GpC-3′ sites

Double-stranded DNA at 5′-GpC-3′ sites refers to specific dinucleotide sequences within the DNA double helix that serve as high-affinity binding sites for various antineoplastic antibiotics. These sites are particularly susceptible to intercalation by drugs like dactinomycin, which utilizes its phenoxazone ring to stack between the guanine-cytosine base pairs while its cyclic peptides occupy the minor groove (Sobell, 1985). This binding mechanism results in the potent inhibition of RNA synthesis, as the drug-DNA complex acts as a physical barrier to the elongation phase of transcription by RNA polymerase (NIH, NCI Drug Dictionary). Because these sequences are prevalent throughout the genome, drugs targeting them are effective against a range of highly proliferative tumors, including Wilms tumor and various sarcomas. However, the relative lack of genomic selectivity leads to significant systemic toxicities, most notably bone marrow suppression and potential cardiotoxicity, which necessitate careful clinical monitoring (StatPearls, Dactinomycin).

Other names

GpC DNA5'-GC-3' DNA sequencesDNA guanine-cytosine stepsGpC dinucleotide sites

Drugs targeting 5′-GpC-3′ sites primarily act through intercalation, where planar aromatic groups insert between the base pairs, or through minor groove binding. This interaction stabilizes the DNA-drug complex, causing local unwinding and structural distortion that physically obstructs the passage of RNA polymerase and DNA polymerase, thereby inhibiting transcription and replication (Sobell, 1985; PubChem CID 2019).